Guest guest Posted June 20, 2008 Report Share Posted June 20, 2008 University of Florida urology officials will collaborate with the German biopharmaceutical firm CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment. CureVac — which specializes in the therapeutic application of messenger RNA, a biomolecule that transfers genetic information from nuclear DNA to cellular protein production machinery — is developing a stabilizedm RNA-derived vaccine for treatment of prostate cancer. Click on the below link for the full story: <http://www.physorg.com/news133010605.html> Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.